hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06285825, orgStudyIdInfo id: 2023-0864, secondaryIdInfos id: NCI-2024-01736, type: OTHER, domain: NCI-CTRP Clinical Registry, briefTitle: A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-31, primaryCompletionDateStruct date: 2026-08-22, completionDateStruct date: 2028-08-22, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: M.D. Anderson Cancer Center, class: OTHER, collaborators name: Sobi, Inc., descriptionModule briefSummary: To look at the safety and effectiveness of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART., conditionsModule conditions: Cytopenia, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: Emapalumab, outcomesModule primaryOutcomes measure: Safety and adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MD Anderson Cancer Center, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Paolo Strati, MD, role: CONTACT, phone: 713-745-1776, email: pstrati@mdanderson.org, contacts name: Paolo Strati, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06285812, orgStudyIdInfo id: 000003, briefTitle: Otitis Treatment With OtoSight™ - Modification of Antibiotic Treatment Intervention in Children, acronym: OTO-MATIC, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-10, primaryCompletionDateStruct date: 2024-05-30, completionDateStruct date: 2024-05-30, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: PhotoniCare, Inc., class: INDUSTRY, collaborators name: TTi Health Research & Economics, descriptionModule briefSummary: A pragmatic, mixed-method trial is to show the ability of OtoSight to change management of the pediatric patient presenting with ear pain in a way that improves patient outcomes and reduces costs., conditionsModule conditions: Otitis Media Acute, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 700, type: ESTIMATED, armsInterventionsModule interventions name: OtoSight Middle Ear Scope, outcomesModule primaryOutcomes measure: Change the clinician rate of antibiotic prescriptions, primaryOutcomes measure: Change the number of antibiotic rounds per patient, primaryOutcomes measure: Change costs associated with management of pediatric patients presenting with ear-related pain, secondaryOutcomes measure: Change in unnecessary antibiotic prescriptions, secondaryOutcomes measure: Change in prescription adherence, secondaryOutcomes measure: Change in antibiotic prescription rate when fluid not present, secondaryOutcomes measure: Improve patient outcomes, secondaryOutcomes measure: Change medical resource utilization, secondaryOutcomes measure: Change unnecessary medical intervention, secondaryOutcomes measure: Impact clinician confidence, secondaryOutcomes measure: Impact caregiver satisfaction, secondaryOutcomes measure: Change in Health-related Quality of Life (HQoL), eligibilityModule sex: ALL, minimumAge: 6 Months, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Children's National Hospital, status: NOT_YET_RECRUITING, city: Washington, state: District of Columbia, zip: 20010, country: United States, contacts name: Bobbe Thomas, role: CONTACT, geoPoint lat: 38.89511, lon: -77.03637, locations facility: Trillim Health, status: RECRUITING, city: Rochester, state: New York, zip: 14620, country: United States, contacts name: Shealynn Hilliard, role: CONTACT, geoPoint lat: 43.15478, lon: -77.61556, locations facility: Cyn3rgy Research, status: RECRUITING, city: Gresham, state: Oregon, zip: 97030, country: United States, contacts name: Allie Calaman, role: CONTACT, geoPoint lat: 45.49818, lon: -122.43148, locations facility: Carolina ENT, status: RECRUITING, city: Orangeburg, state: South Carolina, zip: 29118, country: United States, contacts name: Simone Ansley, role: CONTACT, geoPoint lat: 33.49182, lon: -80.85565, hasResults: False
protocolSection identificationModule nctId: NCT06285799, orgStudyIdInfo id: IHAT_ID_2024, briefTitle: Safety and Effectiveness of Iron Hydroxide Adipate Tartrate (IHAT) in Iron Deficient Premenopausal Women, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-05, primaryCompletionDateStruct date: 2025-12-01, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Nemysis Ltd, class: INDUSTRY, collaborators name: RDC Clinical Pty Ltd, descriptionModule briefSummary: This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed Iron Hydroxide Adipate Tartrate (IHAT) at 2 different dose levels compared to placebo for increasing serum ferritin levels in iron deficient, but otherwise healthy premenopausal women over 12 weeks., conditionsModule conditions: Iron-deficiency, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 180, type: ESTIMATED, armsInterventionsModule interventions name: Low Dose IHAT, interventions name: High Dose IHAT, interventions name: Carob Flour, outcomesModule primaryOutcomes measure: Percentage of women recovering from iron deficiency at week 12, secondaryOutcomes measure: Time to reach normalisation of ferritin levels, secondaryOutcomes measure: Change in iron status, secondaryOutcomes measure: Change in fatigue, secondaryOutcomes measure: Incidence and prevalence of gastrointestinal side effects, secondaryOutcomes measure: Iron deficiency symptoms, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: RDC Clinical Pty Ltd, status: RECRUITING, city: Brisbane, state: Queensland, zip: 4006, country: Australia, contacts name: Amanda Rao, PhD, role: CONTACT, phone: +61 414 488 559, email: amanda@rdcglobal.com.au, contacts name: David Briskey, PhD, role: CONTACT, phone: +61 421 784 077, email: david@rdcglobal.com.au, contacts name: Amanda Rao, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: -27.46794, lon: 153.02809, hasResults: False
protocolSection identificationModule nctId: NCT06285773, orgStudyIdInfo id: Medipol Hospital 36, briefTitle: Recto-intercostal Fascial Plane Block and Pecto-intercostal Fascial Plane Block for Cardiac Surgery, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-25, primaryCompletionDateStruct date: 2024-10-20, completionDateStruct date: 2024-11-10, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Medipol University, class: OTHER, descriptionModule briefSummary: In cardiac surgeries performed with median sternotomy, mediastinal and thoracic tube placement sites are outside the area of effect of parasternal blocks, and sometimes the sternotomy incision extends below the T6 dermatome. Recto intercostal fascial plane block (RIFPB) has been defined as a complementary block for analgesia of this region. This study aims to evaluate the effectiveness of the combination of ultrasound-guided recto-intercostal fascial plane block and pectointercostal fascial block for postoperative analgesia management after open heart surgery (coronary artery bypass) with median sternotomy., conditionsModule conditions: Cardiac Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Sixty patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II and scheduled for open heart surgery (coronary artery bypass) with median sternotomy will be included in the study. Patients will be randomly divided into two groups (Group PR = PIFPB + RIFPB group, Group C = Control group) including 30 patients each, before entering the operating room., primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Outcomes Assessor and participant were blinded to the study, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: RIFPB block, interventions name: Postoperative analgesia management, interventions name: PIFPB block, outcomesModule primaryOutcomes measure: Global recovery scoring system / Quality of Recovery 15 questionairre, secondaryOutcomes measure: Postoperative pain scores (Numerical rating scale) (0-meaning "no pain" to 10-meaning "worst pain imaginable"), secondaryOutcomes measure: The use of rescue analgesia, secondaryOutcomes measure: The use of rescue analgesia, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istanbul Medipol University Hospital, status: RECRUITING, city: Istanbul, state: Bagcilar, zip: 34070, country: Turkey, contacts name: Bahadir Ciftci, MD, role: CONTACT, phone: +905325034428, email: bciftci@medipol.edu.tr, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06285760, orgStudyIdInfo id: 135/23, briefTitle: Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY), acronym: SANDI, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-02, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Puerta de Hierro University Hospital, class: OTHER, collaborators name: Hospital Clinic of Barcelona, collaborators name: Hospital Central de la Defensa Gómez Ulla, collaborators name: Hospital Vall d'Hebron, collaborators name: Hospital Universitario Ramon y Cajal, collaborators name: University Hospital of Girona Dr.Josep Trueta, collaborators name: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa, descriptionModule briefSummary: The goal of this observational study is to assess the natriuretic effect of intravenous acetazolamide in patients admitted with heart failure and persistent congestion despite treatment with intravenous furosemide and sodium-glucose cotransporter type 2 (iSGLT2) inhibitors.The main question it aims to answer is whether there is a difference in natriuresis 48 hours after acetazolamide association to medical treatment recommended by the guidelines (furosemide and ISGLT2)., conditionsModule conditions: Heart Failure, conditions: Persistent Congestion, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 64, type: ESTIMATED, armsInterventionsModule interventions name: Standarized diuretic therapy, outcomesModule primaryOutcomes measure: Change in natriuresis 48 hours after acetazolamide, secondaryOutcomes measure: Increase in diuresis 48 hours after acetazolamide administration, secondaryOutcomes measure: Weight difference 48 hours after acetazolamide administration, secondaryOutcomes measure: Difference in congestion score 48 hours after acetazolamide administration., secondaryOutcomes measure: Difference in ultrasound measurements 48 hours after acetazolamide administration., otherOutcomes measure: Changes in renal function 48 hours after acetazolamide administration., otherOutcomes measure: Ionic (potassium (mmol/L) changes, otherOutcomes measure: chloride (mmol/L) changes 48 hours after acetazolamide administration, otherOutcomes measure: bicarbonate (mmol/L) changes 48 hours after acetazolamide administration, otherOutcomes measure: Changes in blood pressure 48 hours after administration of acetazolamide, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Julia González González, city: Madrid, zip: 28222, country: Spain, contacts name: Julia González González, role: CONTACT, phone: 0034617453693, email: juliagfk@gmail.com, geoPoint lat: 40.4165, lon: -3.70256, hasResults: False
protocolSection identificationModule nctId: NCT06285747, orgStudyIdInfo id: 23-004117, secondaryIdInfos id: NCI-2024-01191, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 23-004117, type: OTHER, domain: Mayo Clinic Institutional Review Board, briefTitle: A Correlational Study: Breast Cancer-related Chest Wall Lymphedema, Quality of Life, and Shoulder Function, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-28, primaryCompletionDateStruct date: 2025-08-01, completionDateStruct date: 2025-08-01, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: This study evaluates how swelling in the chest following breast cancer treatment may affect patients' quality of life and shoulder function., conditionsModule conditions: Breast Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 85, type: ESTIMATED, armsInterventionsModule interventions name: Non-Interventional Study, outcomesModule primaryOutcomes measure: Chest wall lymphedema, primaryOutcomes measure: Quality of life - Limb Lymphoedema Quality of Life (LymQOL), primaryOutcomes measure: Disability of the shoulder - Disabilities of the Arm, Shoulder and Hand (DASH), eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Rochester, status: RECRUITING, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Kayla A. Van Der Weerd, PT, DPT, role: CONTACT, phone: 507-266-8721, email: VanDerWeerd.Kayla@mayo.edu, contacts name: Kayla A. Van Der Weerd, PT, DPT, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06285734, orgStudyIdInfo id: KYLL-202312-049, briefTitle: Clinical Characteristics of Small Intestinal Bacterial Overgrowth in Individuals With Abdominal Distention, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-01-07, completionDateStruct date: 2025-01-07, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Shandong University, class: OTHER, collaborators name: Qilu Hospital of Shandong University (Qingdao), collaborators name: Jinan Central Hospital, collaborators name: Zaozhuang Municipal Hospital, collaborators name: Binzhou Medical University, collaborators name: Weihai Municipal Hospital, collaborators name: Central Hospital of Zibo, collaborators name: Weifang People's Hospital, collaborators name: Qilu hospital of Shandong University Dezhou hospital, collaborators name: Qihe Xian Renmin Hospital, descriptionModule briefSummary: Abdominal distention represents a prevalent clinical manifestation characterized by an unclear etiology and pathogenesis. This symptomatology is frequently observed in various conditions, including small intestinal bacterial overgrowth (SIBO) and abnormal orocecal transit time (OCTT). The utilization of the breath test as a non-invasive diagnostic approach has become widespread in recent years for identifying SIBO and abnormalities in OCTT. In this study, the prevalence of SIBO and OCTT irregularities in individuals presenting with abdominal distention was ascertained through the implementation of the breath test. Furthermore, the correlation between abdominal distention and SIBO/OCTT was analysed to enhance the elucidation of the underlying etiology of abdominal distention. These findings aim to offer valuable insights for refining clinical comprehension and strategies related to the diagnosis and treatment of abdominal distention., conditionsModule conditions: Abdominal Distention, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 402, type: ESTIMATED, armsInterventionsModule interventions name: Breath test, outcomesModule primaryOutcomes measure: Positive rate of SIBO in patients with abdominal distension, secondaryOutcomes measure: Positive rate of abnormal OCTT in patients with abdominal distension, secondaryOutcomes measure: Correlation between clinical features of patients with abdominal distension and SIBO, secondaryOutcomes measure: Correlation between clinical features of patients with abdominal distension and OCTT, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06285695, orgStudyIdInfo id: ILS241-I001, briefTitle: Clareon Toric Study (T2-T9), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-04, primaryCompletionDateStruct date: 2028-04, completionDateStruct date: 2028-04, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Alcon Research, class: INDUSTRY, descriptionModule briefSummary: The purpose of this post-market study is to describe the long-term safety and performance of Clareon Toric Intraocular Lenses (IOLs)., conditionsModule conditions: Aphakia, conditions: Corneal Astigmatism, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Clareon Toric IOL, interventions name: Cataract surgery, outcomesModule primaryOutcomes measure: Mean monocular best corrected distance visual acuity (BCDVA), secondaryOutcomes measure: Mean monocular absolute residual refractive cylinder, secondaryOutcomes measure: Mean absolute IOL rotation from previous visit, secondaryOutcomes measure: Mean absolute IOL rotation from end of surgery supine baseline to each subsequent visit, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Gimbel Eye Centre, status: RECRUITING, city: Calgary, state: Alberta, zip: T3B 0M3, country: Canada, geoPoint lat: 51.05011, lon: -114.08529, locations facility: Uptown Eye Specialists, status: RECRUITING, city: Concord, state: Ontario, zip: L4K 2Z5, country: Canada, geoPoint lat: 43.80011, lon: -79.48291, locations facility: Prism Eye Institute, status: RECRUITING, city: Oakville, state: Ontario, zip: L6H 0J8, country: Canada, geoPoint lat: 43.45011, lon: -79.68292, locations facility: Laurentians Eye Institute, status: RECRUITING, city: Boisbriand, state: Quebec, zip: J7H 0E8, country: Canada, geoPoint lat: 45.61678, lon: -73.83249, locations facility: Bellevue, status: RECRUITING, city: Montréal, state: Quebec, zip: H1V 1G5, country: Canada, geoPoint lat: 45.50884, lon: -73.58781, locations facility: McGill University, status: RECRUITING, city: Montréal, state: Quebec, zip: R7A 3N2, country: Canada, geoPoint lat: 45.50884, lon: -73.58781, hasResults: False
protocolSection identificationModule nctId: NCT06285669, orgStudyIdInfo id: KA18/35, briefTitle: Effects of Kinesiotaping on Respiratory Muscles in Very Preterm Infants, statusModule overallStatus: COMPLETED, startDateStruct date: 2018-01-01, primaryCompletionDateStruct date: 2020-06-30, completionDateStruct date: 2020-06-30, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Ondokuz Mayıs University, class: OTHER, descriptionModule briefSummary: This study aimed to evaluate the effects of kinesio taping on blood gas parameters, respiratory rate, heart rate, oxygen saturation, and pressure limits in preterm infants with RDS who are on NIV. It is hypothesized that the application of kinesio taping to the chest area of preterm infants may improve respiratory functions and oxygenation at the alveolar level, leading to decreased work of breathing, reduced respiratory rate, and improved neonatal stability by promoting respiratory mechanics and enhancing chest expansion., conditionsModule conditions: Preterm, conditions: Premature, conditions: Infant, Newborn, Diseases, conditions: Respiratory Distress Syndrome, conditions: Neonatal Respiratory Distress, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Kinesio-Taping Application, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 26, type: ACTUAL, armsInterventionsModule interventions name: kinesiotaping application, outcomesModule primaryOutcomes measure: Level of pH, eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 4 Months, stdAges: CHILD, contactsLocationsModule locations facility: Nilay Çömük Balci, city: Samsun, state: Atakum, zip: 55139, country: Turkey, geoPoint lat: 41.27976, lon: 36.3361, hasResults: False
protocolSection identificationModule nctId: NCT06285656, orgStudyIdInfo id: ASH-KG, briefTitle: Femoral Blood Gas and Prediction of Postoperative Bleeding, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2024-10-03, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Ankara City Hospital Bilkent, class: OTHER, descriptionModule briefSummary: Postoperative bleeding is still an important concern after major abdominal surgery. Postoperative bleeding is the most important determinant of morbidity and death. It results in longer hospital stays, the necessity for extra radiological tests, interventional radiology treatments, and the possibility of reoperation. Early detection of postoperative bleeding reduces morbidity and mortality with appropriate intervention.Simultaneous arterial and venous blood gas measurements can be used to quickly identify the degree of bleeding and the need for replacement in serious trauma patients brought to the emergency room.Lactate levels, venous oxygen saturation, and the differential in partial pressure of carbon dioxide between arterial and venous blood can all be used to indicate the requirement for replacement, as demonstrated in several studies. The purpose of this study is to evaluate lactate levels, venous oxygen saturation, and arterial-venous partial pressure of carbon dioxide difference in blood gas analysis in order to assess the severity of bleeding in patients undergoing major abdominal surgery as early as possible and perform replacement as soon as possible., conditionsModule conditions: Postoperative Hemorrhage, conditions: Blood Transfusion, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Eritrocyte replacement, secondaryOutcomes measure: Postoperative Hemmorhagea, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False